Renalytix AI (GB:RENX) has released an update.
Renalytix, an AI-driven in vitro diagnostics firm focusing on kidney disease management, has announced the appointment of Oberon Capital as its Joint Corporate Broker to enhance its financial strategies and market presence. This strategic move is aimed at advancing the company’s commitment to improving patient outcomes and supporting value-based healthcare initiatives.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
